Diligence memo · auto-generated · as of July 2, 2026

ZO Skin Health, Inc.

ZO Skin Health, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

ZO Skin Health, Inc. operates in Pharmaceuticals, based in IRVINE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

ZO Skin Health, Inc. has raised $12M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.3M on 2015-01-28.

Most recent recorded round closed around 2017-01-31.

Valuation (modeled)modeled

Provath models ZO Skin Health, Inc. at approximately $186M (range $6.9M–$1.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.04× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era. Within the normal band (104% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 24 months.

Last raise 9.4 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.1× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 58% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 67% of those peers.

Closest niche peers: Arbutus Biopharma Corp, Rvc 360, Llc, Sterrx, Llc, Ribometrix, Inc., Neuraltus Pharmaceuticals, Inc..

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.